Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)
Keros Therapeutics (KROS) posted Income from Continuing Operations of 23461000.0 for Q4 2025, down 222.27% on a QoQ basis from 7280000.0 in Q3 2025, and up 49.03% year-over-year from 15742823.2 in Q4 2024.
Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Keros Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 23461000.0 for Q4 2025.
- Quarterly Income from Continuing Operations rose 49.03% year-over-year to 23461000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 87014000.0 (up 146.44% YoY) and the FY2025 annual result came in at 87014000.0, up 146.44% from the prior year.
- Income from Continuing Operations was 23461000.0 for Q4 2025 at Keros Therapeutics, down from 7280000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 148451000.0 in Q1 2025 and bottomed at 91437000.0 in Q2 2023.
- A 5-year average of 25851150.0 and a median of 28492000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 328.21% — and 2025, when it jumped 444.32%.
- Keros Therapeutics' Income from Continuing Operations stood at 6940000.0 in 2021, then tumbled by 328.21% to 29718000.0 in 2022, then plunged by 53.36% to 45575000.0 in 2023, then slipped by 0.99% to 46026000.0 in 2024, then surged by 49.03% to 23461000.0 in 2025.
- Business Quant data shows KROS's Income from Continuing Operations at 23461000.0 in Q4 2025, 7280000.0 in Q3 2025, and 30696000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | -23.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -45.58 Mn |
| Sep 30, 2023 | -76.88 Mn |
| Jun 30, 2023 | -91.44 Mn |
| Mar 31, 2023 | -39.37 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |
| Mar 31, 2021 | -15.89 Mn |